Imagine designing a clinical trial where:
- Participants who drop out are instantly replaced with new ones who meet your criteria
- Your sample stays representative as populations shift
- No one can meddle with the data based on personal hunches
- Your results get stronger the longer you run it
Sound too good to be true?
That’s basically how global index funds work.
Why trials need diversification (and so do portfolios)
When designing a research trial, you plan for inevitable challenges:
- Variations in how different centres practice
- Differences in patient characteristics
- Loss to follow-up
- A whole site withdrawing from the study
The solution? Diversification and sample size.
A large, diverse population captures the full range of differences between patients, centres, and countries. One outlier patient or underperforming centre can’t tank your entire study when you have hundreds of participants across multiple sites.
Investing works exactly the same way.
A global index fund gives you:
- Massive sample size: hundreds or thousands of companies, not 5–10 hand-picked “winners”
- Broad market exposure: different sectors, sizes, and countries
- Protection from outliers: one failing company barely moves the needle
Just like a well-designed multi-centre trial, your portfolio becomes statistically robust enough to handle individual failures.
Removing human bias from the process
In clinical trials, we bend over backwards to eliminate bias:
- Blinding clinicians and assessors
- Keeping patients unaware of their allocation
- Randomising to remove selection bias
- Using strict protocols to prevent meddling
Why? Because humans skew results — even when we mean well.
The same applies to investing.
Global index funds are passively managed:
No fund manager sits there thinking, “Which companies do I like this year?” A computer simply follows the index rules.
Less meddling = fewer biases = you get the market’s return, not a fund manager’s interpretation of it.
Active fund managers, by contrast, are like unblinded researchers making subjective calls. Sometimes they’re right. Often they’re wrong. Either way, you’re paying them to guess.
The feature researchers wish they had: self-cleansing
Here’s where index funds genuinely outperform clinical trials.
If a company underperforms and drops out of the index, the fund automatically replaces it with the next qualifying company. The structure stays intact. Your portfolio stays current.
Imagine if your research trial could automatically:
- Replenish lost-to-follow-up patients
- Replace protocol violators
- Maintain full sample size and statistical power
- Update inclusion criteria in real time
That’s exactly what index funds do.
Companies that fail? Removed.
Companies that grow? Added.
Your portfolio stays representative without you making a single decision.
The bottom line
When you buy a global index fund, you’re essentially running the gold-standard RCT of investing:
✅ Huge, diverse sample size
✅ Multi-centre design (countries, sectors, sizes)
✅ Protocol-driven, not hunch-driven
✅ Automatically self-correcting
✅ More reliable the longer you run it
You’d never trust a clinical trial with five hand-picked patients from one hospital, run by an unblinded clinician who’s guessing.
So why would you build your retirement portfolio that way?
This is why evidence-based investing = index funds.
⸻
This post is for educational purposes only and does not constitute personalized financial advice.